Hookipa Pharma Stock Surges On HIV Pact With Gilead

Vandana Singh
1 min read
0
In this article:

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).

  • In April 2018, Gilead licensed exclusive rights to Hookipa's arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV).

  • The companies agreed to collaborate through a joint research phase, after which Gilead had rights for further development.

  • Under the amended and restated agreement, Hookipa will advance the HIV program through the Phase 1b trial, with funding from Gilead via an upfront payment and equity purchases.

  • After the Phase 1b trial, Gilead has the exclusive right to assume further development of the program. The HBV portion of the agreement remains unchanged.

  • Hookipa earned a one-time $4 million preclinical milestone payment under the original 2018 agreement.

  • Upon signing of the amended agreement, Hookipa will receive $15 million.

  • In addition, Gilead will make a $5 million equity investment in Hookipa and up to an additional $30 million of equity financing that can be drawn at HOOKIPA's discretion by December 31, 2023.

  • Gilead plans to advance the Hepatitis B virus (HBV) program to the IND-enabling stage in 2022.

  • Price Action: HOOK shares are up 41.8% at $1.90 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories